{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-026910","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2022-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.057170+00:00","generated_at":"2026-06-24T08:34:48.452901+00:00","sec_items":["1.01","2.03","3.02","5.02","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Galectin Therapeutics secures $60M credit line from chairman; CEO extends stock compensation","bullets":["$60M unsecured line of credit from Chairman Richard Uihlein through July 31, 2024; principal & interest due Jan 31, 2026.","Interest at AFR (2.84%) + 2%; conversion price at closing price but not below $3.00 per share.","Initial warrant for 500k shares at $5.00; up to 1.2M additional warrants at 150% of draw closing price (floor $3, cap $10).","CEO Joel Lewis extends 80% stock compensation through Dec 2023; employment term extended to Dec 2024.","Proceeds expected to fund operations through 2024; NAVIGATE phase 2b results expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-026910","json":"https://secwatch.observer/filing/0001140361-22-026910.json","markdown":"https://secwatch.observer/filing/0001140361-22-026910.md","text":"https://secwatch.observer/filing/0001140361-22-026910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/0001140361-22-026910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122026910/brhc10039901_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:34:48.452901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}